CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Has Average Target Price of $10.44

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $10.44.

CAMP has been the topic of several analyst reports. Chardan Capital reduced their target price on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, September 29th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Zacks Research upgraded shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Tuesday, September 29th. Finally, Raymond James Financial assumed coverage on shares of CAMP4 Therapeutics in a report on Friday, October 23rd. They issued a “strong-buy” rating and a $10.00 price objective on the stock.

Read Our Latest Research Report on CAMP4 Therapeutics

CAMP4 Therapeutics Stock Up 2.5%

NASDAQ:CAMP opened at $4.10 on Thursday. CAMP4 Therapeutics has a 52 week low of $2.90 and a 52 week high of $7.75. The stock’s fifty day moving average is $3.84 and its two-hundred day moving average is $4.20. The stock has a market capitalization of $257.29 million, a price-to-earnings ratio of -1.92 and a beta of 0.28.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last released its earnings results on Thursday, November 5th. The Wireless communications provider reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.17). The firm had revenue of $1.90 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,276.33% and a negative return on equity of 182.39%. On average, sell-side analysts expect that CAMP4 Therapeutics will post -0.78 EPS for the current fiscal year.

Insider Transactions at CAMP4 Therapeutics

In other news, Director Andrew Schwab sold 400,000 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the transaction, the director directly owned 2,033,270 shares of the company’s stock, valued at approximately $8,214,410.80. This represents a 16.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kelly Gold acquired 10,000 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was acquired at an average price of $3.96 per share, for a total transaction of $39,600.00. Following the acquisition, the chief financial officer owned 10,000 shares in the company, valued at approximately $39,600. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold a total of 432,028 shares of company stock valued at $1,760,126 over the last ninety days. 21.69% of the stock is owned by company insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jupiter Topco LLC acquired a new stake in CAMP4 Therapeutics during the second quarter worth approximately $27,581,000. Trails Edge Capital Partners LP purchased a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $8,446,935. SummitTX Capital L.P. acquired a new position in shares of CAMP4 Therapeutics in the 1st quarter valued at $1,497,000. BlackRock Inc. acquired a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at $7,185,000. Finally, 5AM Venture Management LLC acquired a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at $25,647,928.

CAMP4 Therapeutics Company Profile

(Get Free Report)

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.

Further Reading

Analyst Recommendations for CAMP4 Therapeutics (NASDAQ:CAMP)

Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.